As Precision Medicine Grows, So Does the Value of Trial Diversity

July 8, 2019

As seen on MedCityNews.com - Posted July 7, 2019 - Original Article


Experts say the rise of cutting-edge new therapies highlighted disparities between clinical trial populations and the patients receiving new drugs. An FDA draft guidance earlier this month sought to address the issue.


The idea of a drug having to undergo clinical trials before becoming eligible for regulatory approval seems simple enough. But while dozens of drugs win approval every year from regulators like the Food and Drug Administration and European Medicines Agency, the studies that lead to their approval are often not demographically reflective of patients in the “real world.” And with the rise of precision medicine, targeted drugs and gene therapies, lack of diversity in clinical trials can make it more challenging to get a complete picture of a drug’s safety-efficacy profile.

Continued on MedCity News

Previous Article
Trial Transparency – Time for Pharma to go Above and Beyond?
Trial Transparency – Time for Pharma to go Above and Beyond?

Next Article
TrialScope Turns to NOL Program, Venture Fund Investment
TrialScope Turns to NOL Program, Venture Fund Investment

Resources from the NJEDA, three venture capital firms and proximity to pharmaceutical giants has helped Tri...